Member Info for Laura2022

Maybe also ask Simon Thompson of investor magazine keeps defending Kromek?

Is “Golden Era” for ADCs in Oncology at Hand? Embracing Their Complexity Is Crucial

Oct 24, 2024

3 Min Read

Paolo Tarantino, MD, Advanced Clinical Research Fellow

Antibody-drug conjugates (ADCs) are among the most rapidly rising treatment modalities in oncology, bringing new hope in the fight against cancer. These compounds leverage decades of research in biologics and cytotoxic molecules, blending the specificity and pharmacokinetics of monoclonal antibodies with the anticancer activity of chemotherapy. Multiple recent clinical successes suggest that the field of ADCs will continue expanding in the coming decades; however, there has also been no lack of negative trials, highlighting the need for awareness about their complex mechanism of action.

Can sell 1.5mln at higher than bid

Much higher

Uxm etc

Half year report to Dec 2024 will usually be late Jan 2025

Think we are on target to BEAT market expectations as we already have £800-900k revenues/income for H1 booked.

Would imagine more contracts and updates on various JVs over next 3 weeks

20mln volune

Mostly buys yesterday..i am sure we'll see a fuller re rate over coming days

Why is that Tricky ?

Wouldn't be surprised to see more RNS over the next few days

Soulac

TRLS and PYC look ready

Jamrock

You've completely contradicted what you were saying just 24hrs ago

Filtered

Please use the sharing tools found via the share button at the top or side of articles. Copying articles to share with others is a breach of FT.com T&Cs and Copyright Policy. Email licensing@ft.com to buy additional rights. Subscribers may share up to 10 or 20 articles per month using the gift article service. More information can be found at https://www.ft.com/tour.

https://www.ft.com/content/85ab8fe2-d1ec-47e9-83f9-4802682a1c94

class of molecules known as antibody-drug conjugates (ADCs) is generating buzz. These use antibodies to deliver chemicals directly to tumours, making them the guided missiles of the cancer world. Invented decades ago, they have recently improved so much that developers such AstraZeneca talk about them replacing conventional chemotherapy. When the UK company and its Japanese partner Daiichi Sankyo revealed impressive breast cancer trial results for their ADC Enhertu in 2022, oncologists broke into a standing ovation.

Jamrock

You are not making sense

For example

About 3 weeks ago

A couple of posters changed tact just a s a few sells came in

It's so obvious

Some people are so transparent

Here we go again from debull

The 850k was a buy yesterday for example

Debull

That's a question for the market makers

But was also difficult to buy into last hour at 0 75p too

Toffee

The overhang went almost 4mths ago

As was pointed out at the time

With all our USA clients like Bicycle and DoseMeRx you wonder whether PYC may consider dual listing down the line

Evening Cbeadle

Yes, shows what PYC can become a leader in its field

10 pence ( £15mln cap) is not beyond PYC

Hi Jungle

This is the start of a proper re valuation of PYC

Had you purchased any ?